Our mission is to help you obtain financial freedom. Checkout Our Youtube Channel Checkout Our Youtube Channel
Blog

MRNA Declines by 17% After Changes to Future Plans

Moderna announced plans to cut $1.1 billion in expenses by 2027 as it adapts to a post-COVID business environment. The company aims to win approval for 10 new products by 2027 but will also pause or scrap some projects to manage R&D spending. Moderna’s shares dropped by over 17% following the news, reflecting concerns about its financial position and delayed profitability until 2028. Despite these cuts, Moderna reported positive results for its vaccines, including respiratory syncytial virus (RSV) and flu shots, with plans to file for approvals. The company expects revenue growth from new product launches between 2026 and 2028. MRNA’s stock has suffered month after month decline, and is approaching a key support zone between $55.80 and $62.62. I would give MRNA some time to bottom out, and I would look for entries around $55-56.

Follow me on social media: https://linktr.ee/realchartchamp

0 Comments
Inline Feedbacks
View all comments

More ClearValue Insights

Default Thumbnail

QQQ Has Rebounded Around $502.60

QQQ continues trading within this range, and has rebounded from the lower end of this range around $502.60. I have $510.31 and $513.40 as my resistance levels ahead, QQQ has struggled to climb above the yellow trendline since Nov. 15.

Read More
Default Thumbnail

SPY Trading Near $601 Resistance

SPY continues to trade near resistance around $601, and has already formed numerous rejections this week. SPY is currently trading above the yellow resistance line, and I would monitor to see if the price remains above $600.83. So far SPY is looking bullish and could trade above $600 for the day.

Read More
Default Thumbnail

RGTI Hit $3.47 Resistance

RGTI has reached my resistance target at $3.47, and there has already been some selling at this price level. I would be cautious of a selloff here, I think RGTI likely has a pullback in the short term.

Read More